ABBOTT LABORATORIES (ABT) Financials
Annual revenue, profitability and per-share results for ABBOTT LABORATORIES, as reported in SEC filings.
Revenue • FY2025
$44.33B
▲ 5.7%YoY
Net income • FY2025
$6.52B
▼ 51.3%YoY
Gross margin • FY2025
56.4%
Diluted EPS • FY2025
$3.72
▼ 51.3%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $44.33B | $6.52B | $25.01B | $3.72 | $7.39B | 18.2% | +5.7% |
| FY2024 | $41.95B | $13.4B | $23.24B | $7.64 | $6.35B | 16.3% | +4.6% |
| FY2023 | $40.11B | $5.72B | $22.13B | $3.26 | $5.06B | 16.2% | -8.1% |
| FY2022 | $43.65B | $6.93B | $24.51B | $3.91 | $7.8B | 19.2% | +1.3% |
Figures as reported in ABBOTT LABORATORIES's 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Financials for companies related to ABT
Never miss a ABT filing.
Get an email when ABT files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.